<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159326</url>
  </required_header>
  <id_info>
    <org_study_id>17309</org_study_id>
    <secondary_id>2014-000829-20</secondary_id>
    <nct_id>NCT02159326</nct_id>
  </id_info>
  <brief_title>Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women</brief_title>
  <official_title>Microgynon Riociguat Drug Interaction Study to Investigate the Effect of Riociguat 2.5 mg 3 Times Daily Multiple-dose Treatment on the Plasma Concentrations of / Exposure to Levonorgestrel and Ethinyl Estradiol in Healthy Postmenopausal Women in a 2-fold Crossover Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Physicians might be concerned that Adempas may have a metabolic interaction with oral
      contraceptives (OC) that could decrease the contraceptive efficacy of the OC. The information
      regarding lack of potential pharmacokinetic interaction has been communicated; there is a
      need for more re-assurance and further data that there is no interaction between Adempas and
      OCs. A drug-drug interaction study of riociguat with an OC such as Microgynon in the least
      vulnerable population for these purposes, i.e. healthy postmenopausal women, is considered
      adequate to inform about safe use of Adempas with OCs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) of Ethinylestradiol (EE)</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Plasma concentrations Ethinyl estradiol (EE) and levonorgestrel (LNG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) of Levonorgestrel (LNG)</measure>
    <time_frame>Up to 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal concentration (Cmax) of Ethinylestradiol (EE)</measure>
    <time_frame>Up to 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal concentration (Cmax) of Levonorgestrel (LNG)</measure>
    <time_frame>Up to 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Drug Interactions</condition>
  <arm_group>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment, a single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microgynon</intervention_name>
    <description>single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)</description>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_label>Arm2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat (Adempas,BAY63-2521)</intervention_name>
    <description>multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment</description>
    <arm_group_label>Arm2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subject

          -  Non-smokers of at least 3 month before screening

          -  Age: 52 to 65 years (inclusive) at the first screening examination

          -  Ethnicity: white

          -  Body mass index (BMI)&gt;=20 and &lt;=32 kg/m2

          -  Postmenopausal state, defined as

          -  Medical history, if applicable (natural menopause at least 12 months before the first
             study drug administration and hormone analyses in serum

          -  Age&lt;60 years: follicle-stimulating hormone (FSH) &gt;40 IU/L in plasma

          -  Age &lt;60 years: estradiol (E2) &lt;20 ng/L (&lt;73 pmol/L) in plasma

        Exclusion Criteria:

          -  History of coronary artery disease, Symptomatic postural hypotension, History of
             bronchial asthma, known hypersensitivity to the study, relevant diseases within 4
             weeks before study drug administration,

          -  Presence or a history of venous or arterial thrombotic / thromboembolic events or
             cerebrovascular accident, a high risk for venous or arterial thrombosis,

          -  Use of systemic or topical medicines or substances which oppose the study objectives,
             smoking, use of sex hormones in any forms

          -  Clinically relevant findings in the ECG, systolic blood pressure below 110 or above
             145 mmHg, heart rate below 50 or above 95 beats per minute

          -  Clinically relevant findings in the gynecological examination,

          -  Participation in another clinical study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>52 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>MÃ¶nchengladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2014</study_first_posted>
  <last_update_submitted>August 13, 2015</last_update_submitted>
  <last_update_submitted_qc>August 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

